Blood markers of inflammation and endothelial dysfunction in cardioembolic stroke: systematic review and meta-analysis

Biomarkers

Volumn 22, Issue 3-4, 2017, Pages 200-209

  Piccardi, Benedetta ^a   Giralt, Dolors ^b   Bustamante, Alejandro ^b   Llombart, Victor ^b   García Berrocoso, Teresa ^b   Inzitari, Domenico ^a,c   Montaner, Joan ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c CNR   (Italy)

Author keywords

biological markers; Cardiovascular disease; stroke

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

CARDIOEMBOLIC STROKE; CAROTID ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; LACUNAR STROKE; MEDLINE; REVIEW; SYSTEMATIC REVIEW; BLOOD; CARDIOVASCULAR DISEASE; COMPLICATION; EMBOLISM; META ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; STROKE; VASCULAR ENDOTHELIUM;

BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EMBOLISM; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; STROKE;

EID: 85017527205     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/1354750X.2017.1286689     Document Type: Review

References (67)

1. Alvarez-Perez, F.J., Castelo-Branco, M., and Alvarez-Sabin, J., 2011. Albumin level and stroke. Potential association between lower albumin level and cardioembolic aetiology. Int J Neurosci, 121, 25–32.
2. Aulin, J., et al., 2015. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J, 170, 1151–1160.
3. Beamer, N.B., et al., 1995. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol, 37, 800–805.
4. Beer, C., et al., 2011. Association of clinical and aetiologic subtype of acute ischaemic stroke with inflammation, oxidative stress and vascular function:a cross-sectional observational study. Med Sci Monit, 17, CR467–CR473.
5. Biteker, M., et al., 2015. Aortic stiffness and plasma brain natriuretic peptide predicts mortality in acute ischemic stroke. Int J Stroke, 10, 679–685.
6. Boos, C.J., Anderson, R.A., and Lip, G.Y., 2006. Is atrial fibrillation an inflammatory disorder? Eur Heart J, 27, 136–149.
7. Burn, J., et al., 1994. Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. Stroke, 25, 333–337. Erratum in:Stroke 1994;25:1887.
8. Bushnell, C.D., and Goldstein, L.B., 2002. Homocysteine testing in patients with acute ischemic stroke. Neurology, 59, 1541–1546.
9. Bustamante, A., et al., 2014. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke:a systematic review and meta-analysis. J Neuroimmunol, 274, 215–224.
10. Cermak, J., et al., 1993. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood, 82, 513–520.
11. Cherian, P., et al., 2003. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke, 34, 2132–2137.
12. Cucchiara, B.L., et al., 2009. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke, 40, 2332–2336.
13. Davis, S.M., and Donnan, G.A., 2012. Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack. N Engl J Med, 366, 1914–1922.
14. den Hertog, H.M., PAIS investigators., et al., 2009. C-reactive protein in the very early phase of acute ischemic stroke:association with poor outcome and death. J Neurol, 256, 2003–2008.
15. Dewan, K.R., and Rana, P.V., 2011. C-reactive protein and early mortality in acute ischemic stroke. Kathmandu Univ Med J (KUMJ), 9, 252–255.
16. Eikelboom, J.W., et al., 2003. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis, 12, 74–81.
17. Eikelboom, J.W., et al., 2000. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke, 31, 1069–1075.
18. García-Berrocoso, T., et al., 2013. B-type natriuretic peptides and mortality after stroke. A systematic review and meta-analysis. Neurology, 23, 1976–1985.
19. Gray, L.J., Virtual International Stroke Trials Archive Collaboration., et al. 2009. Interconversion of the National Institutes of Health Stroke Scale and Scandinavian Stroke Scale in acute stroke. J Stroke Cerebrovasc Dis, 18, 466–468.
20. Guo, Y., Lip, G.Y., and Apostolakis, S., 2012. Inflammation in atrial fibrillation. J Am Coll Cardiol, 60, 2263–2270.
21. Haapaniemi, E., et al., 2007. Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol, 14, 12–17.
22. Hanson, E., et al., 2011. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost, 9, 275–281.
23. Hardie, K., et al., 2005. Trends in five-year survival and risk of recurrent stroke after first-ever stroke in the Perth Community Stroke Study. Cerebrovasc Dis, 19, 179–185.
24. Hart, R.G., Cryptogenic Stroke/ESUS International Working Group., et al. 2014. Embolic strokes of undetermined source:the case for a new clinical construct. Lancet Neurol, 13, 429–438.
25. Hijazi, Z., on behalf of the ARISTOTLE., et al., 2016. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart, 102, 508–517.
26. Hijazi, Z., et al., 2013. Biomarkers in atrial fibrillation:a clinical review. Eur Heart J, 34, 1475–1480.
27. Hu, Y.F., et al., 2015. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol, 12, 230–243.
28. Khan, U., et al., 2008. Homocysteine and its relationship to stroke subtypes in a UK black population:the south London ethnicity and stroke study. Stroke, 39, 2943–2949.
29. Kozuka, K., et al., 2002. Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis, 161, 161–168.
30. Ladenvall, C., et al., 2006. Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke, 37, 2018–2023.
31. Liberati, A., et al., 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:explanation and elaboration. PLoS Med, 6, e1000100.
32. Licata, G., et al., 2009. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost, 101, 929–937.
33. Lindmark, E., et al., 2001. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease:effects of an early invasive or noninvasive strategy. JAMA, 286, 2107–2113.
34. Lip, G.Y., et al., 2007. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation:relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke, 38, 1229–1237.
35. Llombart, V., et al., 2015. B-type natriuretic peptides help in cardioembolic stroke diagnosis:pooled data meta-analysis. Stroke, 46, 1187–1195.
36. Llombart, V., et al., 2013. Cardioembolic stroke diagnosis using blood biomarkers. Curr Cardiol Rev, 9, 340–352.
37. Luo, Y., et al., 2012. Serum CRP concentrations and severity of ischemic stroke subtypes. Can J Neurol Sci, 39, 69–73.
38. Ma, Y., et al., 2010. Homocysteine and ischemic stroke subtype:a relationship study in Chinese patients. Neurol Res, 32, 636–641.
39. Masotti, L., et al., 2005. Prognostic role of C-reactive protein in very old patients with acute ischaemic stroke. J Intern Med, 258, 145–152.
40. Montaner, J., et al., 2008. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke, 39, 2280–2287.
41. Mozaffarian, D., American Heart Association Statistics Committee; Stroke Statistics Subcommittee., et al., 2016. Heart disease and stroke Statistics-2016 Update:A Report From the American Heart Association. Circulation, 133, e38–e60.
42. Muiño, E., et al., 2015. An inflammatory polymorphisms risk scoring system for the differentiation of ischemic stroke subtypes. Mediators Inflamm, 2015, 569714.
43. Nakase, T., et al., 2008. The impact of inflammation on the pathogenesis and prognosis of ischemic stroke. J Neurol Sci, 271, 104–109.
44. Parnetti, L., et al., 2004. Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci, 25, 13–17.
45. Perini, F., et al., 2005. Elevated plasma homocysteine in acute stroke was not associated with severity and outcome:stronger association with small artery disease. Neurol Sci, 26, 310–318.
46. Pietroiusti, A., et al., 2002. Cytotoxin-associated gene-A-positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation, 106, 580–584.
47. Poggesi, A., et al., 2016. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease:a review. J Cereb Blood Flow Metab, 36, 72–94.
48. Purroy, F., et al., 2014. N-terminal pro-brain natriuretic peptide level determined at different times identifies transient ischaemic attack patients with atrial fibrillation. Eur J Neurol, 21, 679–683.
49. Rajeshwar, K., et al., 2012. C-reactive protein and nitric oxide levels in ischemic stroke and its subtypes:correlation with clinical outcome. Inflammation, 35, 978–984.
50. Ribo, M., et al., 2004. Role of homocysteine in the acute phase of stroke. Neurologia, 19, 10–14.
51. Ridker, P.M., et al., 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 336, 973–979.
52. Shibazaki, K., et al., 2009. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med, 48, 259–264.
53. Sonneveld, M.A., et al., 2013. Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients. Atherosclerosis, 230, 210–215.
54. Terruzzi, A., et al., 2008. C-reactive protein and aetiological subtypes of cerebral infarction. Neurol Sci, 29, 245–249.
55. Turgut, B., et al., 2011. Differences in platelet-leukocyte aggregates among subtypes of acute cerebral ischemia. J Neurol Sci, 305, 126–130.
56. Tuttolomondo, A., et al., 2012. Inflammation in ischemic stroke subtypes. Curr Pharm Des, 18, 4289–4310.
57. Tuttolomondo, A., et al., 2009. Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes:relationship with TOAST subtype, outcome and infarct site. J Neuroimmunol, 215, 84–89.
58. Üstündağ, M., et al., 2010. The role of serum ferritin, pro-brain natriuretic peptide and homocysteine levels in determining ischaemic stroke subtype, severity and mortality. Hong Kong Journal of Emergency Medicine, 17, 13–21.
59. VanGilder, R.L., et al., 2014. C-reactive protein and long-term ischemic stroke prognosis. J Clin Neurosci, 21, 547–553.
60. Vila, N., et al., 2000. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke, 31, 2325–2329.
61. Vila, N., et al., 2000. Interaction between interleukin-6 and the natural anticoagulant system in acute stroke. J Interferon Cytokine Res, 20, 325–329.
62. Wiseman, S., et al., 2014. Blood markers of coagulation, fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke:systematic review and meta-analysis. Cerebrovasc Dis, 37, 64–75.
63. Wu, N., et al., 2015. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation:a systematic review and meta-analysis. Can J Cardiol, 31, 278–286.
64. Yin, W.H., et al., 2004. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J, 147, 931–938.
65. Yokokawa, H., et al., 2008. Prevalence of metabolic syndrome and serum marker levels in patients with four subtypes of cerebral infarction in Japan. J Clin Neurosci, 15, 769–773.
66. Yokote, H., et al., 2007. Acute multiple brain infarction in large-artery atherosclerosis is associated with hyperhomocyst(e)inemia. Acta Neurol Scand, 116, 243–247.
67. Zhixin, W., et al., 2013. The value of the use of plasma B-type natriuretic peptide among acute ischemic stroke patients in a Chinese emergency department. Clin Neurol Neurosurg, 115, 1671–1676.